Connect Biopharma is trading 9.6% up at $2.50, though no confirmed company-specific catalyst was identified for August 21, 2026.
- The latest material update remains the August 12 quarterly report, which noted completed enrollment in two Phase 2 studies and expected September topline results.
- Broader pre-market sentiment is positive, with the Nasdaq Composite up 0.60%, but that modest gain does not clearly explain the stock’s larger move.